REGENXBIO INC. DL-,0001 WKN: A140E0 ISIN: US75901B1070 Kürzel: RB0 Forum: Aktien Thema: Hauptdiskussion

https://finance.yahoo.com/news/regenxbio-announces-rgx-314-data-110500392.html

Chardan Capital Stick to Their Buy Rating for RegenXBio https://www.investing.com/news/chardan-capital-stick-to-their-buy-rating-for-regenxbio-2614547

AbbVie and REGENXBIO Announce Eye Care Collaboration https://www.prnewswire.com/news-releases/abbvie-and-regenxbio-announce-eye-care-collaboration-301374836.html - AbbVie and REGENXBIO form a strategic partnership combining eye care and gene therapy expertise - Companies will develop and commercialize RGX-314, an investigational gene therapy for wet age-related macular degeneration, diabetic retinopathy and other chronic retinal diseases - REGENXBIO to receive $370 million upfront payment ...

REGENXBIO Reports Second Quarter 2021 Financial Results and Operational Highlights https://www.prnewswire.com/news-releases/regenxbio-reports-second-quarter-2021-financial-results-and-operational-highlights-301351442.html

REGENXBIO and Abeona update on arbitration of licensing dispute https://seekingalpha.com/news/3716050-regenxbio-and-abeona-update-on-arbitration-of-licensing-dispute

REGENXBIO Presents Additional Positive Interim Data from Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at American Society of Gene and Cell Therapy's 24th Annual Meeting https://www.prnewswire.com/news-releases/regenxbio-presents-additional-positive-interim-data-from-phase-iii-trial-of-rgx-121-for-the-treatment-of-mps-ii-hunter-syndrome-at-american-society-of-gene-and-cell-therapys-24th-annual-meeting-301291376.html • RGX-121, a one-time gene therapy for MPS II, continues to be well-tolerated with no drug-related serious adverse events • Biomarkers and measures of neurodevelopmental function from patients in Cohorts 1 and 2 continue to indicate CNS activity following RGX-121 administration • Evidence of systemic enzyme expression and biomarker activity continues to be observed • REGENXBIO recently initiated dosing of patients in Cohort 3 ...

https://www.prnewswire.com/news-releases/regenxbio-reports-first-quarter-2021-financial-results-and-operational-highlights-301284916.html

REGENXBIO Announces Dosing of First Patient in Cohort 3 of Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) https://www.prnewswire.com/news-releases/regenxbio-announces-dosing-of-first-patient-in-cohort-3-of-phase-iii-trial-of-rgx-121-for-the-treatment-of-mps-ii-hunter-syndrome-301269209.html • First patient dosed at third dose level in ongoing trial of RGX-121, a one-time gene therapy for MPS II; total of nine patients have been dosed at four leading clinical centers in the U.S. and Brazil  • Previously reported positive interim data from Cohorts 1 and 2 demonstrated consistent reductions in CNS biomarkers, continued neurocognitive development, and evidence of systemic effects ...

Regenxbio: 4Q Earnings Snapshot https://www.sfchronicle.com/business/article/Regenxbio-4Q-Earnings-Snapshot-15990371.php REGENXBIO Reports Fourth Quarter and Full-Year 2020 Financial Results and Operational Highlights https://www.prnewswire.com/news-releases/regenxbio-reports-fourth-quarter-and-full-year-2020-financial-results-and-operational-highlights-301237754.html

REGENXBIO Announces Additional Positive Interim Phase I/IIa and Long-Term Follow-Up Data of RGX-314 for the Treatment of Wet AMD https://www.prnewswire.com/news-releases/regenxbio-announces-additional-positive-interim-phase-iiia-and-long-term-follow-up-data-of-rgx-314-for-the-treatment-of-wet-amd-301228344.html ...

REGENXBIO patent case may weigh on Sarepta, according to Morgan Stanley https://seekingalpha.com/news/3660139-regenxbio-patent-case-may-weigh-on-sarepta-according-to-morgan-stanley • Morgan Stanley analyst Matthew Harrison writes that a patent case filed by REGENXBIO Inc. (NASDAQ:RGNX) against Sarepta Therapeutics (NASDAQ:SRPT) regarding SRP-9001 and SRP-9003 could have implications for the company. • In late December, a federal judge denied a motion from Sarepta Therpeutics (SRPT) to dismiss a lawsuit filed by Wilson Wolf Manufacturing Corp. regarding SRP-9001. • Harrison notes that REGENEXBIO "may be able to obtain a higher royalty based on its AAV patent (a mid-to-high single-digit royalty) than Wilson Wolf can likely obtain based on its cell-culture-device patent (a low single-digit royalty)." • Sarepta has also filed a motion to dismiss the REGENXBIO case. • Harrison maintains an equal-weight rating on the stock and a $95 price target.

🎯

https://www.wfmz.com/news/pr_newswire/pr_newswire_business/regenxbio-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwriters-option/article_face8711-b686-5c26-b70e-60d65205afa4.html

REGENXBIO Announces Proposed Public Offering Of Common Stock https://www.prnewswire.com/news-releases/regenxbio-announces-proposed-public-offering-of-common-stock-301202287.html

REGENXBIO Announces Update on RGX-314 and Pivotal Program for the Treatment of Wet AMD and New Gene Therapy Program for the Treatment of Duchenne Muscular Dystrophy https://www.prnewswire.com/news-releases/regenxbio-announces-update-on-rgx-314-and-pivotal-program-for-the-treatment-of-wet-amd-and-new-gene-therapy-program-for-the-treatment-of-duchenne-muscular-dystrophy-301201378.html

REGENXBIO Announces Agreement to Monetize Portion of Zolgensma Royalties for $200 Million https://www.prnewswire.com/news-releases/regenxbio-announces-agreement-to-monetize-portion-of-zolgensma-royalties-for-200-million-301197818.html Agreement with Healthcare Royalty enables REGENXBIO to advance its broad gene therapy pipeline, including pivotal program for RGX-314 ...